Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer
A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.
Media Type: Html
- SourceUrl: https://www.cancer.gov/publishedcontent/syndication/1070677.htm
- Syndication ID: 19293
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Monday, March 23, 2020 at 07:12 PM
- Date Syndication Updated: Monday, August 03, 2020 at 06:25 AM
Embed Code Snippet
To get the embed code snippet please Login.
